Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4125020 | 0.92 | ADORA2A (0.54) | ADORA2AADORA3CCNE1CDK2CCNE2 | |
| SCHEMBL1412172 | 0.86 | NT5E (0.42) | ADORA2AADORA3ADORA1 | |
| SCHEMBL4127533 | 0.85 | CCNE1 (0.50) | ADORA2ACCNE1CDK2CCNE2CCNA2 | |
| SCHEMBL1402061 | 0.85 | ADORA2A (0.51) | ADORA2AADORA3ADORA1 | |
| SCHEMBL1402039 | 0.83 | ADORA2A (0.50) | ADORA2AADORA3ADORA1 | |
| SCHEMBL4110298 | 0.83 | ADORA2A (0.51) | ADORA2AADORA3 | |
| SCHEMBL4124284 | 0.83 | ADORA2A (0.48) | ADORA2AADORA3ADORA1 | |
| SCHEMBL4131726 | 0.82 | CCNE1 (0.45) | ADORA2AADORA3CCNE1CDK2CCNE2 | |
| SCHEMBL4117867 | 0.82 | ADORA2A (0.63) | ADORA2AADORA3ADORA1 | |
| SCHEMBL4125024 | 0.81 | ADORA2A (0.40) | ADORA2AADORA3CCNE1CDK2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | CYP3A43, OXER1, OPRM1 | ADORA2A 2082/4885ADORA3 554/4885CCNE1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.